Tropical Journal of Pharmaceutical Research

Case Report | OPEN ACCESS

A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (DiabegardÂ®), a Polypeptide Isolated from the Seeds of Momordica charantia Linn

Yong Yean Sirn¹, Lee Cheng Lok¹, Zuraini Ahmad^2,3, Muhammad Nazrul Hakim^2,3,4

¹Well Again Clinic Holistic Healthcare, 46150, Petaling Jaya; ²Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400; ³Halal Product Research Institute, Universiti Putra Malaysia, 43400; ⁴Sports Academy, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

For correspondence:- Muhammad Hakim Email: nazrul.hakim@gmail.com Tel:+60389471126

Received: 25 March 2014 Accepted: 2 April 2014 Published: 24 September 2014

Citation: Sirn YY, Lok LC, Ahmad Z, Hakim MN. A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (DiabegardÂ®), a Polypeptide Isolated from the Seeds of Momordica charantia Linn. Trop J Pharm Res 2014; 13(9):1555-1560 doi: 10.4314/tjpr.v13i9.25

© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To assess six patients with Diabegard® supplementation with reference to cholesterol profiles.

Methods: We report the clinical courses of six individuals taking Diabegard® supplementation at 60 and 120 mg/day for 8 weeks.

Results: Patients had a maximum of 52.13 % reduction in low-density lipoprotein (LDL) cholesterol, 47.67 % reduction in triglycerides and 35.78 % reduction in total cholesterol (TC) within 8 weeks of Diabegard® supplementation. Interestingly, high-density lipoprotein (HDL) cholesterol increased by approximately 23.29 %. Patients also had reduced readings for C-reactive protein (CRP) and homocysteine (with maximum reduction of 81.58 % and 57.41 % respectively). In some patients, these parameters were elevated prior to supplementation.

Conclusion: These results suggest that supplementation of Diabegard® will improve patients’ cholesterol profile by reduction of LDL and TC. Patients also expressed lower CRP and homocysteine indicating reduced inflammation and reduction of cardiovascular diseases (CVD) risk. However, patients taking this supplementation are advised to seek medical consultation in monitoring their cholesterol and other biochemical profile levels.

Keywords: Hypocholesterolemia, DiabegardÂ®, Momordica charantia, C-reactive protein, Inflammation, Cardiovascular disease